Joseph S. Dillon, PhD, MBA

Joseph S. Dillon, PhD, MBA, is Chairman & CEO of SynerPhysics, Inc. and President of Dillon Capital Strategies, the strategy and business analytics advisory arm of SynerPhysics. Dr. Dillon is a seasoned pharmaceutical executive with over 30 years of experience. He has extensive experience in global pharmaceutical business development, planning and analysis, corporate finance, M&A, licensing, and technology/deal valuations. Dr. Dillon has valued over 450 deals in negotiation and has been a lead on nearly 50 strategic transactions with a value exceeding $20B. He has consulted dozens of companies and held senior positions, including CEO, CBO, and CFO at select clients. Prior to this, Dr. Dillon held senior positions in pharmaceutical management consulting firms, most significantly as Senior Vice President, Head of Corporate Development Services and Valuations for The Mattson Jack Group/KantarHealth. Other previous positions include CEO, President, and Director of The Pharmaceutical Development Center (sold to AAI), a pharmaceutical developer and manufacturer; Executive Vice President and CFO of Vail Banks Inc., a multi-bank holding company (lead IPO, then sold to US Bancorp); CFO and Treasurer of Oread Inc., a contract pharmaceutical developer and manufacturer; and corporate positions with predecessor companies of Sanofi. Dr. Dillon is Past-Chairperson of the Licensing Executive Society Life Sciences Sector. He is a veteran speaker at BIO, LES, WBR, EBD, and other prominent industry organization events. Dr. Dillon holds a PhD in metaphysical sciences/theoretical physics, an MBA in international finance, with emphasis in investment banking, and a bachelor’s degree in finance.